R Laing

Summary

Country: New Zealand

Publications

  1. ncbi 2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung
    Amy J Scott-Thomas
    Christchurch School of Medicine and Health Sciences, Department of Pathology, University of Otago, Christchurch, 8140, New Zealand
    BMC Pulm Med 10:56. 2010
  2. ncbi Community-acquired pneumonia: influence of management practices on length of hospital stay
    R Laing
    Canterbury Respiratory Research Group, New Zealand
    Intern Med J 34:91-7. 2004
  3. ncbi Community-acquired pneumonia in Christchurch and Waikato 1999-2000: microbiology and epidemiology
    R Laing
    Canterbury Respiratory Research Group, Christchurch School of Medicine and Health Sciences, University of Otago
    N Z Med J 114:488-92. 2001
  4. ncbi Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
    W S Lim
    Respiratory Infection Research Group, Respiratory Medicine, Nottingham City Hospital, Nottingham NG5 1PB, UK
    Thorax 58:377-82. 2003
  5. ncbi Optimizing antibiotic therapy-the Aberdeen experience
    Y Kumarasamy
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, UK
    Clin Microbiol Infect 9:406-11. 2003

Collaborators

  • I M Gould
  • Amy J Scott-Thomas
  • W S Lim
  • Y Kumarasamy
  • Michael Epton
  • Stephen T Chambers
  • Philip K Pattemore
  • Mona Syhre
  • John Pearson
  • B Jappy
  • I A Gillanders
  • M M van der Eerden
  • T Cadwgan
  • W G Boersma
  • J T Macfarlane
  • S A Lewis
  • G I Town
  • N Karalus

Detail Information

Publications5

  1. ncbi 2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung
    Amy J Scott-Thomas
    Christchurch School of Medicine and Health Sciences, Department of Pathology, University of Otago, Christchurch, 8140, New Zealand
    BMC Pulm Med 10:56. 2010
    ..Growth of Ps. aeruginosa releases a "grape-like" odour that has been identified as the microbial volatile organic compound 2-aminoacetophenone (2-AA)...
  2. ncbi Community-acquired pneumonia: influence of management practices on length of hospital stay
    R Laing
    Canterbury Respiratory Research Group, New Zealand
    Intern Med J 34:91-7. 2004
    ..To identify variation in the management of -community-acquired pneumonia between two New Zealand hospitals and the factors that may account for any differences...
  3. ncbi Community-acquired pneumonia in Christchurch and Waikato 1999-2000: microbiology and epidemiology
    R Laing
    Canterbury Respiratory Research Group, Christchurch School of Medicine and Health Sciences, University of Otago
    N Z Med J 114:488-92. 2001
    ..Ongoing surveillance of antibiotic resistance and variations in the prevalence of organisms causing community-acquired pneumonia is required to guide clinicians' empiric antibiotic use...
  4. ncbi Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
    W S Lim
    Respiratory Infection Research Group, Respiratory Medicine, Nottingham City Hospital, Nottingham NG5 1PB, UK
    Thorax 58:377-82. 2003
    ..The validation cohort confirmed a similar pattern. CONCLUSIONS: A simple six point score based on confusion, urea, respiratory rate, blood pressure, and age can be used to stratify patients with CAP into different management groups...
  5. ncbi Optimizing antibiotic therapy-the Aberdeen experience
    Y Kumarasamy
    Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, UK
    Clin Microbiol Infect 9:406-11. 2003
    ....